Engineered human antibodies for the opsonization and killing of
Amino Acid Sequence
Antibodies, Bacterial
/ genetics
Antibodies, Monoclonal
/ genetics
Antibody-Dependent Cell Cytotoxicity
/ immunology
Complement Activation
Dose-Response Relationship, Drug
Dose-Response Relationship, Immunologic
Humans
Opsonization
/ immunology
Phagocytosis
/ immunology
Protein Binding
Protein Engineering
/ methods
Protein Interaction Domains and Motifs
/ genetics
Receptors, Fc
/ genetics
Staphylococcal Protein A
/ immunology
Staphylococcus aureus
/ immunology
C1q
FcRn
Staphylococcus aureus
engineered antibody
immune evasion
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
25 01 2022
25 01 2022
Historique:
accepted:
09
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
1
3
2022
Statut:
ppublish
Résumé
Gram-positive organisms with their thick envelope cannot be lysed by complement alone. Nonetheless, antibody-binding on the surface can recruit complement and mark these invaders for uptake and killing by phagocytes, a process known as opsonophagocytosis. The crystallizable fragment of immunoglobulins (Fcγ) is key for complement recruitment. The cell surface of
Identifiants
pubmed: 35058363
pii: 2114478119
doi: 10.1073/pnas.2114478119
pmc: PMC8795526
pii:
doi:
Substances chimiques
Antibodies, Bacterial
0
Antibodies, Monoclonal
0
Receptors, Fc
0
Staphylococcal Protein A
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI148543
Pays : United States
Informations de copyright
Copyright © 2022 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
Competing interest statement: The authors are inventors of patents describing therapeutic antibodies against Staphylococcus aureus. D.M. declares a competing financial interest as a founder of ImmunArtes LLC, a University of Chicago startup company that aims to develop vaccines and therapies against S. aureus infections.
Références
Nat Rev Microbiol. 2015 Sep;13(9):529-43
pubmed: 26272408
EBioMedicine. 2016 Nov;13:328-338
pubmed: 27789272
Proc Natl Acad Sci U S A. 2016 May 17;113(20):5718-23
pubmed: 27140614
Nature. 1994 Nov 24;372(6504):379-83
pubmed: 7969498
Structure. 1995 Mar 15;3(3):265-78
pubmed: 7788293
Mol Immunol. 1993 Oct;30(14):1279-85
pubmed: 8413328
Nature. 1991 Apr 4;350(6317):423-6
pubmed: 1901381
Biochemistry. 1981 Apr 28;20(9):2361-70
pubmed: 7236608
J Immunol. 2000 May 15;164(10):5313-8
pubmed: 10799893
mBio. 2013 Aug 27;4(5):e00575-13
pubmed: 23982075
FASEB J. 2009 Oct;23(10):3393-404
pubmed: 19525403
J Immunol. 1989 Apr 15;142(8):2778-83
pubmed: 2495325
Immunol Lett. 2017 Sep;189:64-72
pubmed: 28554712
Proc Natl Acad Sci U S A. 2020 Sep 15;117(37):22992-23000
pubmed: 32855300
J Exp Med. 2016 Mar 7;213(3):293-301
pubmed: 26880578
MAbs. 2018 Oct;10(7):1098-1110
pubmed: 29947573
Mol Immunol. 1979 Sep;16(9):697-701
pubmed: 119162
Immunol Rev. 2016 Nov;274(1):33-58
pubmed: 27782325
Front Cell Infect Microbiol. 2017 May 05;7:166
pubmed: 28529927
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9337-42
pubmed: 18599440
Int J Antimicrob Agents. 2012 Mar;39(3):193-200
pubmed: 22226649
Immunity. 2017 Jul 18;47(1):159-170.e10
pubmed: 28723548
Immunol Lett. 1992 Feb 15;31(3):259-65
pubmed: 1372285
Eur J Immunol. 1976 Mar;6(3):207-13
pubmed: 1086776
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1574-9
pubmed: 24434550
Comput Methods Programs Biomed. 2010 Sep;99(3):306-14
pubmed: 20176408
Science. 2014 Mar 14;343(6176):1260-3
pubmed: 24626930
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):
pubmed: 33563762
Nat Immunol. 2017 Aug;18(8):889-898
pubmed: 28604720
Clin Microbiol Rev. 2015 Jul;28(3):603-61
pubmed: 26016486
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Microbiol Mol Biol Rev. 2021 Jan 27;85(1):
pubmed: 33504655
Cell Microbiol. 2013 Dec;15(12):1955-68
pubmed: 23869880
mBio. 2015 Jan 06;6(1):
pubmed: 25564466
Nat Commun. 2011 Dec 20;2:599
pubmed: 22186895
J Infect Dis. 2019 Feb 23;219(6):884-888
pubmed: 30551184
Immunology. 1989 Aug;67(4):460-5
pubmed: 2527804
J Immunol. 2020 Sep 15;205(6):1593-1600
pubmed: 32769122
Trends Pharmacol Sci. 2016 Mar;37(3):231-241
pubmed: 26719219
Front Med (Lausanne). 2021 Mar 05;7:616524
pubmed: 33748151
J Exp Med. 2014 Nov 17;211(12):2331-9
pubmed: 25348152
Int Immunol. 2001 Dec;13(12):1551-9
pubmed: 11717196
J Bacteriol. 2018 Apr 9;200(9):
pubmed: 29440258
Scand J Immunol. 1982 Mar;15(3):275-8
pubmed: 7089488
Int Immunol. 2006 Dec;18(12):1759-69
pubmed: 17077181
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5399-404
pubmed: 10805799
Antimicrob Agents Chemother. 2006 Aug;50(8):2751-5
pubmed: 16870768
Nature. 1988 Apr 21;332(6166):738-40
pubmed: 3258649
J Exp Med. 2010 Aug 30;207(9):1863-70
pubmed: 20713595
Infect Immun. 2012 Oct;80(10):3460-70
pubmed: 22825452